Fortrea Holdings Inc.

NasdaqGS:FTRE Stok Raporu

Piyasa değeri: US$1.2b

Fortrea Holdings Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Fortrea Holdings kazanç ve gelirin sırasıyla yıllık 78.1% ve 2.8% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 76.1% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 12.8% olacağı tahmin edilmektedir.

Anahtar bilgiler

78.1%

Kazanç büyüme oranı

76.11%

EPS büyüme oranı

Life Sciences kazanç büyümesi17.6%
Gelir büyüme oranı2.8%
Gelecekteki özkaynak getirisi12.85%
Analist kapsamı

Good

Son güncelleme14 May 2026

Gelecekteki son büyüme güncellemeleri

Recent updates

Anlatı Güncellemesi • May 07

FTRE: Execution Risk Around 2026 Revenue Guidance Will Cap Future Upside

Analysts have raised their price targets on Fortrea by $3 to $5, and the fair value estimate in this model has shifted from $5.0 to $9.5 as analysts point to moderating discount rate assumptions, slightly positive revenue growth, and higher expected profit margins reflected in a higher forward P/E multiple. Analyst Commentary Recent research on Fortrea shows a split view, with some firms raising price targets by US$3 to US$5, while others have taken a more cautious stance, trimming targets and questioning how much upside is already reflected in the valuation.
Anlatı Güncellemesi • Apr 21

FTRE: Conservative 2026 Guidance And AI Tools May Support Re Rating

The analyst price target for Fortrea has been reset from about $22.59 to $16.00 as analysts factor in updated fair value assumptions, slightly lower revenue growth and profit margin inputs, and a lower future P/E multiple, while also incorporating recent Street research that adjusts targets across firms in response to evolving views on the company's fundamentals and guidance. Analyst Commentary Recent Street research on Fortrea shows a mix of trimmed price targets and selective upgrades, as analysts recalibrate their models around updated guidance and sector views.
Anlatı Güncellemesi • Apr 07

FTRE: Margin Recovery Under New Leadership And Conservative 2026 Guidance May Drive Re Rating

Analysts nudged their price target for Fortrea slightly higher to $22.59 from $22.46, citing a mix of higher assumed profit margins, a lower future P/E multiple, and varied recent Street calls that balance upgraded ratings with trimmed targets in the $12 to $22 range. Analyst Commentary Recent Street research on Fortrea shows a wide range of opinions, but the most optimistic voices point to improving execution, clearer profit potential, and room for the shares to rerate as fundamentals stabilize.
Anlatı Güncellemesi • Mar 24

FTRE: Margin Recovery And Deleveraging Under New Leadership May Drive Re Rating

Narrative Update The analyst price target for Fortrea has been revised lower from about $25 to roughly $22.46. This reflects analysts balancing recent price target cuts from several banks with more constructive views that cite improving execution, better fundamentals, and a clearer path to margin recovery under new leadership.
Anlatı Güncellemesi • Mar 09

FTRE: Margin Recovery And 2026 Guidance Under New Leadership Will Drive Upside

The analyst price target for Fortrea Holdings has shifted lower by about $2 to align with a refreshed fair value estimate of $14.44, as analysts factor in a higher discount rate, more cautious revenue growth assumptions, and only modestly revised margin and P/E inputs, despite recent rating upgrades and mixed target resets across the Street. Analyst Commentary Street research on Fortrea paints a mixed picture, with several firms turning more constructive on execution and earnings power, while others temper expectations for share price upside through lower targets.
Anlatı Güncellemesi • Feb 23

FTRE: Execution Improvements And Deleveraging Under New Leadership May Drive Re Rating

Narrative Update on Fortrea Holdings: Analyst Price Target Shift The updated analyst price target for Fortrea Holdings reflects a higher implied valuation in dollar terms. Analysts are citing improved execution under new leadership, a clearer path to margin recovery, and recent target increases from firms that now see better revenue trends, margin potential, and benefits from deleveraging.
Analiz Makalesi • Feb 12

The Market Doesn't Like What It Sees From Fortrea Holdings Inc.'s (NASDAQ:FTRE) Revenues Yet As Shares Tumble 33%

Fortrea Holdings Inc. ( NASDAQ:FTRE ) shares have retraced a considerable 33% in the last month, reversing a fair...
Anlatı Güncellemesi • Feb 09

FTRE: Execution And Margin Recovery Under New Leadership Will Drive Future Upside

Narrative Update: Fortrea Holdings Our updated analyst price target for Fortrea moves higher by about $3, with analysts pointing to improving execution under new leadership, early commercial traction, a clearer path to margin recovery, and more supportive biopharma demand as key reasons for their revised expectations. Analyst Commentary Recent Street research on Fortrea reflects a more constructive tone, with several bullish analysts lifting price targets and upgrading ratings as they reassess the company’s execution, growth prospects, and margin potential.
Anlatı Güncellemesi • Jan 25

FTRE: Execution Gains And Biopharma Cycle Tailwinds May Drive Re Rating

Narrative Update on Fortrea Holdings Analysts have lifted their blended price expectations for Fortrea by several dollars, with new targets in the low to mid $20s and up to $25, citing improving execution under new leadership, a clearer path to margin recovery, and better perceived performance as the biopharma cycle picks up. This is broadly consistent with only modest tweaks to our discount rate, revenue growth, margin and future P/E assumptions and no change to our $25.00 fair value estimate.
Anlatı Güncellemesi • Jan 11

FTRE: New Leadership And Margin Recovery Path May Drive Re Rating

Analysts have raised their blended price target on Fortrea Holdings to about $25 from roughly $13, reflecting updated assumptions for stronger revenue growth, slightly improved profit margins, and a higher future P/E multiple, alongside recent upgrades and target increases from several firms. Analyst Commentary Bullish analysts are becoming more constructive on Fortrea Holdings, with a series of upgrades and price target increases that highlight improving company execution and a more supportive setup for profitability and valuation.
Anlatı Güncellemesi • Dec 27

FTRE: Rapid Share Gains Will Be Tested By Leadership Execution Risks

Analysts have nudged their average price target on Fortrea Holdings higher, from $12.07 to $13.25, citing encouraging early progress under new leadership, a steady Q3 book-to-bill backdrop, and signs that contract research and healthcare utilization trends may be stabilizing into 2026. Analyst Commentary Recent research updates reflect a cautiously constructive stance on Fortrea, with incremental target price hikes tied to operational progress and a stabilizing industry backdrop.
Anlatı Güncellemesi • Dec 13

FTRE: Rapid Share Gains Will Face Test From Leadership Transition Execution

Analysts have raised their fair value estimate for Fortrea Holdings from $11.21 to $12.07 per share, citing a lower perceived discount rate, slightly stronger long term revenue growth assumptions, and improving demand signals reflected in multiple recent price target increases across the Street. Analyst Commentary Bullish analysts point to a constructive setup for Fortrea as recent price target increases cluster in a narrow range above the prior consensus, suggesting growing confidence that execution under new leadership can support a re-rating.
Analiz Makalesi • Dec 07

Fortrea Holdings Inc. (NASDAQ:FTRE) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Despite an already strong run, Fortrea Holdings Inc. ( NASDAQ:FTRE ) shares have been powering on, with a gain of 27...
Anlatı Güncellemesi • Nov 29

FTRE: Rapid Share Price Increase Will Challenge Upside Amid Mixed Industry Trends

Analysts have raised their average price target for Fortrea Holdings. Recent targets have moved from approximately $7-11 previously to as high as $14, reflecting improving internal execution, stabilizing industry trends, and cautious optimism regarding future demand.
Seeking Alpha • Nov 20

Fortrea Holdings: Showing Real Signs Of Life

Summary Fortrea Holdings has shown signs of recovery after severe operational and financial struggles, with shares rebounding from historic lows. The company reported improving sales momentum and a rising backlog, but EBITDA and margins remain under pressure, keeping leverage high. Management has implemented cost reductions, raised guidance, and enacted a shareholder rights plan, signaling renewed urgency and insider confidence. While the darkest scenarios seem less likely, conviction to buy remains low; continued monitoring is warranted as recovery progresses. Read the full article on Seeking Alpha
Anlatı Güncellemesi • Nov 15

FTRE: Bookings Stability And Leadership Transition Will Shape Outlook Into 2026

Fortrea Holdings' analyst price target has increased significantly from $9.53 to $11.21, as analysts cite a more promising outlook supported by steady bookings, sector stabilization, and improving market demand. Analyst Commentary Recent analyst research highlights both positive developments and ongoing uncertainties for Fortrea Holdings.
Anlatı Güncellemesi • Nov 01

FTRE: Stabilizing Healthcare Trends Will Support Resilience Amid Mixed Market Signals

The analyst price target for Fortrea Holdings has been raised from $7 to a range between $9 and $10. Analysts cite stabilizing healthcare cost trends and improving contract research bookings as key factors for their more optimistic outlook.
Anlatı Güncellemesi • Oct 18

Global Demographic Trends Will Spur Clinical Advances

Analysts have raised their price target for Fortrea Holdings from $8.30 to $9.44, citing sustained improvements in revenue growth, stabilizing cost trends, and recent industry signals that point to a bottoming in contract research organization demand. Analyst Commentary Recent analyst updates highlight a shifting outlook for Fortrea Holdings, with both optimistic and cautious perspectives emerging from the latest research notes.
Anlatı Güncellemesi • Oct 03

Global Demographic Trends Will Spur Clinical Advances

Analysts have raised their fair value estimate for Fortrea Holdings from $7.89 to $8.30 per share. They cite recent improvements in industry bookings and biotech funding, despite continued mixed demand signals.
Anlatı Güncellemesi • Sep 05

Global Demographic Trends Will Spur Clinical Advances

The upward revision in Fortrea Holdings’ price target is primarily driven by a lower discount rate, signaling reduced perceived risk and supporting the increase in fair value from $7.44 to $7.89. What's in the News Fortrea Holdings raised its full-year 2025 revenue guidance to $2.6–$2.7 billion.
Analiz Makalesi • Aug 14

Health Check: How Prudently Does Fortrea Holdings (NASDAQ:FTRE) Use Debt?

NasdaqGS:FTRE 1 Year Share Price vs Fair Value Explore Fortrea Holdings's Fair Values from the Community and select...
Anlatı Güncellemesi • Aug 07

Global Demographic Trends Will Spur Clinical Advances

Fortrea Holdings’ price target has been revised upward to $7.02, primarily due to solid earnings visibility and positive physician survey results for hospital segments, despite cost challenges in managed care and a neutral outlook in clinical laboratories. Analyst Commentary Earnings visibility remains solid for hospital-focused segments.
Analiz Makalesi • Jun 21

Why Fortrea Holdings Inc. (NASDAQ:FTRE) Could Be Worth Watching

Fortrea Holdings Inc. ( NASDAQ:FTRE ), is not the largest company out there, but it led the NASDAQGS gainers with a...
User avatar
Yeni Anlatı • May 17

New Therapeutic Areas And AI Adoption Will Fuel Progress

Expanding into therapeutic areas and strengthening partnerships may increase revenue through diversified client engagement.
Analiz Makalesi • May 08

Is There An Opportunity With Fortrea Holdings Inc.'s (NASDAQ:FTRE) 49% Undervaluation?

Key Insights Fortrea Holdings' estimated fair value is US$11.03 based on 2 Stage Free Cash Flow to Equity Fortrea...
Analiz Makalesi • Apr 08

Is Fortrea Holdings (NASDAQ:FTRE) Using Debt Sensibly?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Seeking Alpha • Mar 06

Fortrea: A Growing CRO With Strong Backlog, Margin Expansion, And Industry Tailwinds

Summary FTRE's strong backlog of $7.7 billion provides revenue stability and planning advantages, despite short-term spin-off costs and missed earnings. The CRO market is projected to grow significantly, driven by increased outsourcing of complex late-stage trials, positioning FTRE for long-term growth. FTRE's global reach across 90 countries offers a competitive advantage in multi-region trials, enhancing patient enrollment and administrative efficiency. Post-spin-off, FTRE can focus on high-margin areas like oncology and decentralized trials, with expected margin improvements from reduced overhead costs. Read the full article on Seeking Alpha
Analiz Makalesi • Mar 04

Benign Growth For Fortrea Holdings Inc. (NASDAQ:FTRE) Underpins Stock's 38% Plummet

To the annoyance of some shareholders, Fortrea Holdings Inc. ( NASDAQ:FTRE ) shares are down a considerable 38% in the...
Analiz Makalesi • Dec 27

We Think Fortrea Holdings (NASDAQ:FTRE) Has A Fair Chunk Of Debt

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Seeking Alpha • Dec 26

Fortrea: Turning Around As The Activists Move In

Summary Fortrea, a recent Labcorp spin-off, is poised for recovery with strong bookings, industry inflection, and activist interest, despite a 46% stock drop in 2024. CEO Thomas Pike's proven track record and the potential January Effect add to Fortrea's upside, targeting a $45 stock price within a year. The CRO industry's temporary downturn is reversing, with Fortrea's book-to-bill ratio improving to 1.23x, indicating strong future revenue growth. Fortrea's high leverage and ongoing spin-off expenses are concerns, but activist involvement and potential acquisition post-July 2025 offer additional upside. Read the full article on Seeking Alpha
Seeking Alpha • Nov 28

Fortrea: Some Green Shoots After A Dismal Period

Summary Fortrea faces challenges with falling sales, lack of earnings, and high leverage, despite some positive signs in the third quarter. The company, spun off from Labcorp, operates in an interesting CRO sector, yet results are underwhelming. While leverage remains high, potential EBITDA improvements and reduced separation costs offer a roadmap for future growth, but risks like AI disruption remain. Read the full article on Seeking Alpha
Analiz Makalesi • Nov 21

There Is A Reason Fortrea Holdings Inc.'s (NASDAQ:FTRE) Price Is Undemanding

Fortrea Holdings Inc.'s ( NASDAQ:FTRE ) price-to-sales (or "P/S") ratio of 0.6x might make it look like a strong buy...

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:FTRE - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/20282,806-171631679
12/31/20272,693-4612213411
12/31/20262,607-75795511
3/31/20262,709-447190221N/A
12/31/20252,723-98688114N/A
9/30/20252,760-1,028-132N/A
6/30/20252,734-1,030-103-88N/A
3/31/20252,686-755145164N/A
12/31/20242,696-271237263N/A
9/30/20242,709-246226264N/A
6/30/20242,748-244233268N/A
3/31/20242,811-119111145N/A
12/31/20232,843-32128168N/A
9/30/20232,89550129178N/A
6/30/20232,943127196257N/A
3/31/20233,01116887146N/A
12/31/20222,8371462883N/A
12/31/20213,05898143170N/A
12/31/20202,580-359177201N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: FTRE önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: FTRE önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: FTRE önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: FTRE şirketinin gelirinin (yıllık 2.8% ) US pazarından (yıllık 11.7% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: FTRE şirketinin gelirinin (yıllık 2.8% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: FTRE 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 12.8 %).

Büyüyen şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/05/22 20:15
Gün Sonu Hisse Fiyatı2026/05/22 00:00
Kazançlar2026/03/31
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Fortrea Holdings Inc. 13 Bu analistlerden 11, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Eric ColdwellBaird
Luke SergottBarclays
Michael RyskinBofA Global Research